RLY-4008 is a highly selective inhibitor designed to target FGFR2, a protein that can be involved in the growth of certain types of cancer cells. This medication is being studied for its potential to treat patients with intrahepatic cholangiocarcinoma, a type of liver cancer, as well as other advanced solid tumors. The trial aims to determine the maximum tolerated dose and the recommended dose for further studies. It also evaluates the safety, tolerability, and effectiveness of RLY-4008 in shrinking tumors or stopping their growth.

Cholangiocarcinoma – Cholangiocarcinoma is a type of cancer that forms in the bile ducts, which are the tubes that carry bile from the liver to the gallbladder and small intestine. It often begins in the cells lining the bile ducts and can occur anywhere along these ducts. The disease may cause symptoms such as jaundice, abdominal pain, and weight loss as it progresses. It is typically classified based on its location as intrahepatic, perihilar, or distal cholangiocarcinoma. The progression of the disease can lead to the obstruction of bile flow, causing further complications.

Advanced Solid Tumors – Advanced solid tumors refer to a group of cancers that have formed solid masses in various organs or tissues and have progressed to an advanced stage. These tumors can occur in different parts of the body, such as the lungs, breast, prostate, or colon. As they grow, they may invade nearby tissues and spread to other parts of the body, a process known as metastasis. Symptoms vary depending on the tumor’s location and size but may include pain, swelling, or organ dysfunction. The progression of these tumors can lead to significant health challenges as they affect the normal function of the affected organs.